No Data
No Data
Mitchell Kapoor Reaffirms Buy Rating for Summit Therapeutics Amid Promising Ivonescimab Trial Results
Truist Financial Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Jefferies Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $31
Cantor Fitzgerald Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Why Summit Therapeutics Inc. (SMMT) Went Up On Wednesday
Health Care Ticks Up Ahead of Earnings -- Health Care Roundup